Comprehensive analysis of lung adenocarcinoma patients with gefitinib as first-line, second-line and third-line treatment

作者：Liu, Daoming; Wang, Fei; Chen, Xia^*; Shi, Hong

来源：International Journal of Clinical and Experimental Medicine, 2016, 9(10): 20171-20178.

• Lung adenocarcinoma
• prognosis factor
• gefitinib
• tumor stage
• EGFR mutation
• metastasis

Objective: To evaluate the prognostic factors of overall survival (OS) and progression-free survival (PFS) of lung adenocarcinoma patients received gefitinib as first-line, second-line and third-line treatment. Methods: Total of 43 lung adenocarcinoma patients hospitalized in Taian City Central Hospital of Shandong province from May 2006 to August 2012 were incorporated into our retrospective study according to the inclusion and exclusion criteria. The mean follow-up was 20.4 +/- 9.1 months. The information of patients was recorded as gender, age, smoking, complications, organ metastasis (liver, bone, brain and adrenal gland), tumor stage, EGFR (epidermal growth factor receptor) mutation, adverse effect, gefitinib-response, gefitinib therapeutic regimen. Chi-square test and t-test were performed to analyze collection data, Log-rank was performed to univariate analysis of OS and PFS among groups. Results: The median overall survival of 43 patients was 19 months (95% confidence interval: 16-22 months). Univariate analysis displayed that tumor stage, EGFR mutation and organ metastasis were prognostic factors of OS and PFS (P<0.05); gender, age, smoking, complications, organ metastasis, tumor stage, EGFR mutation, adverse effect, gefitinib therapeutic regimen were not prognostic factors of OS and PFS among groups. Conclusion: Tumor stage, EGFR mutation and organ metastasis were prognostic factors of OS and PFS of lung adenocarcinoma patients.

• 出版日期2016
• 单位泰安市中心医院